OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection
Christina M. Arieta, Yushu Joy Xie, Daniel Rothenberg, et al.
Cell (2023) Vol. 186, Iss. 11, pp. 2392-2409.e21
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission
Julia M. Adler, Ricardo Martin Vidal, Christine Langner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus
Min Lin, Yifan Yin, Xiaomeng Zhao, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1

The Immunogenicity of Coxsackievirus A6 (D3a Sub‐Genotype) Virus‐Like Particle and mRNA Vaccines
Huanhuan Lu, Jinbo Xiao, Jingdong Song, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Closed Access | Times Cited: 1

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history
Hailey Hornsby, Alexander R. Nicols, Stéphanie Longet, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 27

T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19
Reza Zonozi, Lucy C. Walters, Aaron Shulkin, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 724
Closed Access | Times Cited: 26

T cell immune memory after covid-19 and vaccination
Lulu Wang, Alexander R. Nicols, Lance Turtle, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000468-e000468
Open Access | Times Cited: 25

Advanced technologies for the development of infectious disease vaccines
Akash Gupta, Arnab Rudra, Kaelan Reed, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 12, pp. 914-938
Closed Access | Times Cited: 7

Vaccine process technology—A decade of progress
Barry C. Buckland, Gautam Sanyal, Todd Ranheim, et al.
Biotechnology and Bioengineering (2024) Vol. 121, Iss. 9, pp. 2604-2635
Open Access | Times Cited: 6

The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Gaurav Shrivastava, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-18
Open Access | Times Cited: 5

N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
Sevastyan O. Rabdano, Ellina Ruzanova, Anastasiya Evgenievna Vertyachikh, et al.
Journal of Infection (2024), pp. 106288-106288
Open Access | Times Cited: 5

Distinct CD8+ T-cell types Associated with COVID-19 Severity in Unvaccinated HLA-A2+ Patients
Kazuya Masuda, Sho Iketani, Lihong Liu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response
Charles O. Noble, Ellie McDonald, Suellen Nicholson, et al.
Journal of Infection (2025), pp. 106436-106436
Open Access

Combined immunization with SARS-CoV-2 spike and SARS-CoV nucleocapsid protects K18-hACE2 mice but increases lung pathology
Jae‐Kwan Kim, A. V. Kachko, Prabhuanand Selvaraj, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access

Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
Masaud Shah, Sung Ung Moon, Ji‐Yon Shin, et al.
Advanced Science (2025)
Open Access

T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases
Xin Song, Yongfeng Li, Hongxia Wu, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1181-1181
Open Access | Times Cited: 4

UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease
Chang Yi Wang, Be-Sheng Kuo, Yu-Hsiang Lee, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108887-108887
Open Access | Times Cited: 3

The HLA-II immunopeptidome of SARS-CoV-2
Shira Weingarten-Gabbay, Da‐Yuan Chen, Siranush Sarkizova, et al.
Cell Reports (2023) Vol. 43, Iss. 1, pp. 113596-113596
Open Access | Times Cited: 8

Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection
John T. Bates, Seth T. Lirette, Andrew P. Farmer, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2

Page 1 - Next Page

Scroll to top